One of my focus areas has been hepatology, especially Hepatitis C and NASH. Regarding the latter, investors have focused primarily on Intercept Pharmaceuticals (ICPT, market cap. $4.8 billion), and to a lesser extent on Genfit (GNFT, market cap. $1.2 Billion). Gilead has been given very little credit for its drug, simtuzumab. On the more speculative investment side, Galectin Therapeutics (GALT, market cap. $300 million) is in phase 1 with its lead drug GR-MD-02, a galectin-3 inhibitor. This drug may be effective in treating more severe forms of NASH, which is extremely valuable from a pharmacoeconomic perspective. The company will be hosting a conference call Tuesday morning to discuss Phase 1 data. This company has excellent management and is targeting the appropriate patient population.
Disclosure: The author is long ICPT, GILD, GALT, GNFTF.